Lantern Pharma Inc Stock Price, News & Analysis

Lantern Pharma (LTRN) has received FDA clearance for its IND application to begin a Phase 1b/2 clinical trial of LP-184 in Triple Negative Breast Cancer (TNBC). The trial will evaluate LP-184 through two approaches: a monotherapy arm with approximately 30 advanced-stage TNBC patients, and a combination therapy with olaparib for second-line TNBC patients with BRCA1/2 alterations. LP-184, developed using Lantern's AI platform RADR®, is a novel small molecule that targets DNA damage in cancer cells. The drug previously received FDA Orphan Drug Designation (2023) and Fast Track Designation (2024) for TNBC treatment. The trials will be conducted in the US, India, and Nigeria, targeting regions with high TNBC incidence. The global TNBC market opportunity exceeds $4 billion annually, with over 300,000 new cases diagnosed worldwide each year.

Lantern Pharma (NASDAQ: LTRN) reported its Q4 and full-year 2024 results, highlighting significant progress in its AI-driven oncology drug development programs. The HARMONIC™ trial for LP-300 showed an impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with expansion in Japan and Taiwan. LP-184 received two FDA Fast Track Designations for Glioblastoma and Triple Negative Breast Cancer, plus three Rare Pediatric Disease Designations.

The company's RADR® AI platform surpassed 100 billion oncology-specific data points in 2024. Financial results showed cash position of $24.0 million as of December 31, 2024. Q4 net loss was $5.9 million ($0.54 per share), compared to $4.2 million ($0.39 per share) in Q4 2023. Full-year 2024 net loss per share was $1.93 versus $1.47 in 2023.

Lantern Pharma (NASDAQ: LTRN), an AI-driven cancer therapy development company, has scheduled its fourth quarter and fiscal year 2024 financial results webcast for Thursday, March 27th, 2025, at 4:30 PM ET. The presentation will be led by President and CEO Panna Sharma, accompanied by the management team.

During the webcast, management will discuss:

• Q4 and full-year 2024 operating and financial results
• Upcoming milestones and clinical trials
• Development updates on the RADR® AI and machine learning platform

The company develops targeted cancer therapies using its proprietary RADR® AI platform and has multiple clinical-stage drug programs in development.

Lantern Pharma (NASDAQ: LTRN) announced the publication of its PCT patent application for a novel machine learning solution predicting blood-brain barrier (BBB) permeability. The technology has shown exceptional performance, processing up to 100,000 molecules per hour with industry-leading accuracy, with Lantern's AI algorithms holding five of the top eleven positions on the Therapeutic Data Commons Leaderboard.

The proprietary technology integrates advanced molecular representation techniques with synthetic data augmentation, processed by machine learning algorithms through Lantern's RADR® AI platform. The company's subsidiary, Starlight Therapeutics, plans to implement this technology for STAR-001 development. The PCT application allows Lantern to pursue worldwide patent protection for 20 years from filing, with expedited review initiated in the United States.

Lantern Pharma (NASDAQ: LTRN) has announced advancements in its RADR® AI platform for optimizing antibody-drug conjugate (ADC) development. The company's AI-driven approach has successfully identified 82 promising ADC targets and 290 target-indication combinations, while validating 729 potential payload molecules from over 50,000 compounds.

The research demonstrated that 22 targets have been clinically validated, while 60 novel targets present new intellectual property opportunities. The platform's payload molecules showed exceptional potency with GI50 values from picomolar to 10 nM ranges. According to the company, this AI-driven approach could reduce ADC development timelines by 30-50% and cut costs by up to 60% compared to traditional methods.

The global ADC market is projected to reach $30.4 billion by 2028, growing at a CAGR of 41.7%. The company is advancing multiple ADC candidates through preclinical development, including a collaboration with the MAGICBULLET::Reloaded Initiative at the University of Bielefeld.

Lantern Pharma (NASDAQ: LTRN) has announced the enrollment and dosing of its first patient in Taiwan for the Phase 2 HARMONIC™ clinical trial of LP-300. The trial targets never-smoker patients with non-small cell lung cancer (NSCLC) who have progressed after tyrosine kinase inhibitor treatment.

The expansion into Taiwan is strategically significant as over 50% of lung cancer cases there occur in never-smokers. The trial follows encouraging preliminary results showing an 86% clinical benefit rate and 43% objective response rate among the first seven patients.

The Phase 2 trial will enroll up to 90 patients across two treatment arms: 60 patients receiving LP-300 with standard chemotherapy, and 30 receiving standard chemotherapy alone. The study will compare progression-free survival and median overall survival between the groups.

Lantern Pharma (NASDAQ: LTRN) announced that its drug candidate LP-184 received FDA Fast Track Designation for treating Triple Negative Breast Cancer (TNBC), marking its second such designation in 2024 following one for Glioblastoma. TNBC affects approximately 29,000 patients annually in the US, with over 50% relapsing within 3-5 years. LP-184, currently in Phase 1A clinical trials, has shown significant preclinical efficacy in TNBC models, including tumor regression of 107-141% in PDX models. The drug has demonstrated promising synergy with checkpoint inhibitors and effectiveness against PARP inhibitor-resistant cases.

Lantern Pharma and its subsidiary Starlight Therapeutics presented new preclinical data and Phase 1b trial design for LP-184 (STAR-001) in glioblastoma at SNO 2024. The data shows LP-184 combined with spironolactone increases GBM cell sensitivity up to 6-fold through ERCC3 degradation. The drug demonstrates favorable brain penetrance and effectiveness in temozolomide-resistant GBM models. Currently in Phase 1a trials, LP-184 has shown no dose-limiting toxicities across nine patient cohorts. The planned Phase 1b trial will evaluate LP-184 as both monotherapy and in combination with spironolactone in patients with IDH wild type GBM at first progression.

Lantern Pharma (NASDAQ: LTRN) has announced the first patient dosing in Japan for its Phase 2 HARMONIC™ clinical trial of LP-300 in never-smoker NSCLC patients. The trial, now expanded to ten sites across Japan and Taiwan, focuses on patients who have progressed after TKI treatment. Initial results from the U.S. trial showed an 86% clinical benefit rate and 43% objective response rate among the first seven patients. The expansion is significant as NSCLC in never-smokers occurs 2-3 times more frequently in East Asian countries, with Japan reporting 33-40% of new lung cancer cases in never-smokers.